Biotechnology company Scholar Rock has raised $20m in a series A round featuring Kraft Group that will fund the development of novel biologic therapeutics.
US-based biotechnology company Scholar Rock has raised $20m in series A funding from investors including conglomerate Kraft Group.
Venture capital firms Arch Venture Partners, which led the round, Polaris Partners and EcoR1 Capital also took part, alongside Scholar Rock founder Timothy Springer.
Scholar Rock focuses on discovering and developing niche modulators that can work at the site of a disease withoutb side effects. The funding will be used to advance its proprietary modulators from the preclinical research stage toward clinical…
